Enveric Biosciences Inc (ENVB)

$1.96 -0.02 (-1.01%)
Market Cap 8.47M
Revenue (ttm) 0.00
Net Income (ttm) -8.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 83,400
Avg Vol 4,775,296
Day's Range N/A - N/A
Shares Out 3.68M
Stochastic %K 80%
Beta 1.24
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuro...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 444 8400
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
Meri7
Meri7 Jun. 4 at 6:31 PM
$ENVB looks like the bottom…can move quick and fill that gap over 4 dollars.
0 · Reply
Tofer85
Tofer85 Jun. 4 at 3:54 PM
$ENVB needs to break $2.10 for leg up then past $2.35 to hit 3+
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:37 AM
$ENVB $CLIK $SKYQ $DSY fame
0 · Reply
bioebi
bioebi May. 29 at 2:08 PM
$CMND $ENVB ENVB and CMND go hand in hand both working on same drug class both very low flow
1 · Reply
bioebi
bioebi May. 29 at 1:44 PM
$CMND $ENVB ENVB: very low float beaten down in same group as CMND
0 · Reply
bioebi
bioebi May. 29 at 1:42 PM
$CMND $ENVB ENVB has much better pipeline in the same class
0 · Reply
Rrrrrtttyuu
Rrrrrtttyuu May. 29 at 1:14 AM
$ENVB Does anyone know the results of the shareholder meeting? Please share!
0 · Reply
Rrrrrtttyuu
Rrrrrtttyuu May. 29 at 1:13 AM
$ENVB Does anyone know the results of the shareholder meeting? Please share!
0 · Reply
Fede_Tech
Fede_Tech May. 28 at 2:14 PM
0 · Reply
Fede_Tech
Fede_Tech May. 28 at 2:12 PM
$ENVB We are talking about a 5x opportunity here. Just be prepared.
0 · Reply
Latest News on ENVB
Enveric Biosciences initiates IND-enabling Genotoxicity studies of EB-003

2026-06-02T13:40:18.000Z - 2 days ago

Enveric Biosciences initiates IND-enabling Genotoxicity studies of EB-003

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Enveric Biosciences reports preclinical results from analysis of EB-003

2026-05-19T12:19:47.000Z - 16 days ago

Enveric Biosciences reports preclinical results from analysis of EB-003

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

May 19, 2026, 8:00 AM EDT - 16 days ago

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year

2026-05-15T13:30:05.000Z - 20 days ago

Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year

Enveric Biosciences sees cash runway into 1Q27

2026-05-15T13:28:31.000Z - 20 days ago

Enveric Biosciences sees cash runway into 1Q27

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

May 15, 2026, 8:00 AM EDT - 20 days ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026

Enveric issued U.S. patent for methods of treating psychiatric disorders

2026-05-13T16:39:18.000Z - 22 days ago

Enveric issued U.S. patent for methods of treating psychiatric disorders

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

May 13, 2026, 8:00 AM EDT - 22 days ago

Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders

Enveric Biosciences highlights preclinical data for EB-003

2026-05-05T12:19:49.000Z - 4 weeks ago

Enveric Biosciences highlights preclinical data for EB-003

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

Enveric Biosciences trading resumes

2026-04-30T19:26:43.000Z - 5 weeks ago

Enveric Biosciences trading resumes

Enveric Biosciences trading halted, volatility trading pause

2026-04-30T13:43:15.000Z - 5 weeks ago

Enveric Biosciences trading halted, volatility trading pause

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Apr 28, 2026, 7:33 AM EDT - 5 weeks ago

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

LABT

Enveric Biosciences files to sell 6.82M shares of common stock

2026-04-23T23:30:54.000Z - 6 weeks ago

Enveric Biosciences files to sell 6.82M shares of common stock

3 Penny Stocks to Watch Now, 4/21/26

2026-04-21T17:19:08.000Z - 6 weeks ago

3 Penny Stocks to Watch Now, 4/21/26

PBM TOVX

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 6 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX GHRS HELP

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 17, 2026, 6:28 PM EDT - 6 weeks ago

Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences prices $13.9M at-the-market offering

2026-04-17T00:05:12.000Z - 7 weeks ago

Enveric Biosciences prices $13.9M at-the-market offering

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 16, 2026, 8:00 PM EDT - 7 weeks ago

Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences secures new U.S. patent for its EVM301 series

2026-03-31T12:12:19.000Z - 2 months ago

Enveric Biosciences secures new U.S. patent for its EVM301 series

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Mar 27, 2026, 5:40 PM EDT - 2 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

Enveric Biosciences Announces Registration of Five Trademarks

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Enveric Biosciences Announces Registration of Five Trademarks

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Feb 25, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Feb 19, 2026, 8:00 AM EST - 3 months ago

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 29, 2026, 8:00 AM EST - 4 months ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 5:00 PM EST - 4 months ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 4 months ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces Patent Issuance

Dec 29, 2025, 8:00 AM EST - 5 months ago

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 12, 2025, 4:46 PM EST - 6 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 6 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 9, 2025, 8:00 AM EST - 6 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Dec 4, 2025, 8:00 AM EST - 6 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 26, 2025, 8:00 AM EST - 6 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Nov 14, 2025, 4:05 PM EST - 7 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 8 months ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 8 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 8 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 8 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 8 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 9 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 9 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 9 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 9 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 10 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 10 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 11 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 11 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 1 year ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 1 year ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 1 year ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 1 year ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Meri7
Meri7 Jun. 4 at 6:31 PM
$ENVB looks like the bottom…can move quick and fill that gap over 4 dollars.
0 · Reply
Tofer85
Tofer85 Jun. 4 at 3:54 PM
$ENVB needs to break $2.10 for leg up then past $2.35 to hit 3+
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 10:37 AM
$ENVB $CLIK $SKYQ $DSY fame
0 · Reply
bioebi
bioebi May. 29 at 2:08 PM
$CMND $ENVB ENVB and CMND go hand in hand both working on same drug class both very low flow
1 · Reply
bioebi
bioebi May. 29 at 1:44 PM
$CMND $ENVB ENVB: very low float beaten down in same group as CMND
0 · Reply
bioebi
bioebi May. 29 at 1:42 PM
$CMND $ENVB ENVB has much better pipeline in the same class
0 · Reply
Rrrrrtttyuu
Rrrrrtttyuu May. 29 at 1:14 AM
$ENVB Does anyone know the results of the shareholder meeting? Please share!
0 · Reply
Rrrrrtttyuu
Rrrrrtttyuu May. 29 at 1:13 AM
$ENVB Does anyone know the results of the shareholder meeting? Please share!
0 · Reply
Fede_Tech
Fede_Tech May. 28 at 2:14 PM
0 · Reply
Fede_Tech
Fede_Tech May. 28 at 2:12 PM
$ENVB We are talking about a 5x opportunity here. Just be prepared.
0 · Reply
Fede_Tech
Fede_Tech May. 26 at 2:21 PM
$ENVB a new spike seems possible for the following days. Chart is talking…
0 · Reply
Fede_Tech
Fede_Tech May. 25 at 9:56 PM
$ENVB
1 · Reply
Luckyjs38
Luckyjs38 May. 22 at 1:02 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 May. 22 at 10:55 AM
$ENVB Time to Load up before the Massive news Ind, government grants, mile stone payments, abbvie settlement lots of potential here
0 · Reply
d_risk
d_risk May. 21 at 9:52 AM
$ENVB - Enveric Biosciences, Inc. - 10Q - Updated Risk Factors ENVB flags a new risk: extreme stock volatility and volume spikes could trigger Nasdaq Limit Up-Limit Down trading halts, restricting investor trading when demand is highest and potentially amplifying volatility and hurting liquidity. #Biotechnology #StockVolatility #TradingHalts #MarketLiquidityRisk #NasdaqRegulation 🟢 Added 🟠 Removed https://d-risk.ai/ENVB/10-Q/2026-05-15
0 · Reply
Luckyjs38
Luckyjs38 May. 20 at 7:51 PM
$ENVB This stock is finally no longer restricted! Time to load up 🥰
0 · Reply
Luckyjs38
Luckyjs38 May. 20 at 1:47 PM
$ENVB
0 · Reply
HeinBlood
HeinBlood May. 20 at 12:17 PM
$ENVB I'm well positioned again for the next up move. E.g. waiting for an license agreement between ENVB and AbbVie and related royalties.
0 · Reply
PiviotPoint
PiviotPoint May. 19 at 2:59 PM
$ENVB looks just like $CMND chart yesterday be careful looks like the same game plane might be at work.
0 · Reply
Luckyjs38
Luckyjs38 May. 19 at 1:13 PM
$ENVB Absolutely criminal what these racketeering market makers are doing with short exemptions at $ENVB @Enveric_Bio Company has more cash on hand than its current market cap. Has great scientific findings with their drug candidate EB-003 and they short and manipulate it on positive news. These shorts will inevitably be annihilated. They don’t understand the science here. I do.
0 · Reply
2TrustHim
2TrustHim May. 19 at 12:25 PM
$ENVB Awesome Update!!!
0 · Reply
DARKP00L
DARKP00L May. 19 at 12:08 PM
$ENVB 08:06 on May. 19 2026 Enveric Biosciences Reports Preclinical Results From Preclinical In Vitro Experiments Evaluating Photoxicity Risk, Indicates No Photoreactive Potential For EB-003 #tradeideas
0 · Reply